Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q04724

UPID:
TLE1_HUMAN

ALTERNATIVE NAMES:
E(Sp1) homolog; Enhancer of split groucho-like protein 1

ALTERNATIVE UPACC:
Q04724; A8K495; Q5T3G4; Q969V9

BACKGROUND:
Transducin-like enhancer protein 1, alternatively named E(Sp1) homolog or Enhancer of split groucho-like protein 1, serves as a crucial transcriptional corepressor. It interacts with multiple transcription factors to inhibit NF-kappa-B-regulated gene expression and Wnt signaling. Its ability to modulate transcriptional activation by FOXA2, CTNNB1, and TCF family members, along with enhancing FOXG1/BF-1- and HES1-mediated transcriptional repression, highlights its significant role in gene regulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Transducin-like enhancer protein 1 offers a promising avenue for developing novel therapeutic approaches. Its central role in regulating critical signaling pathways presents it as an attractive target for therapeutic intervention in disease mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.